Back to top

Analyst Blog

Zacks Equity Research

Accenture Wins More Deals

ACN IBM

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Accenture Plc. (ACN - Analyst Report) is using its technical know-how to its advantage, banking on which the company has been winning several major deals.

Recently, insurance company Crum & Forster selected Accenture’s Duck Creek Policy Administration software to facilitate Duck Creek’s rating and policy processing system for commercial lines, which will help them improve upon their workers’ compensation process.

This apart in a separate contract, the company also won a Biosurveillance contract Recently, the U.S. Department of Homeland Security (DHS) awarded a $3 million contract to Accenture to improve biosurveillance operations of Office of Health Affairs (OHA). This is expected to help data sharing and collaboration between Homeland Security, OHA and its partners.

To fuel growth, the company has adopted a three-tier strategy to grow the business in line with economic growth. The company has set new priorities and has started growing its core business, which includes management consulting, technology and business process outsourcing.

At the same time, Accenture is making significant investments in new business and technology that could generate growth in the future. We believe that the frequent deal wins are positive outcomes of these strategic moves. We are encouraged by the steady flow of new businesses and believe that the trend will continue.

Moreover, the company is also growing inorganically and gaining access to new technologies through meaningful acquisitions. However, increasing competition from IBM Corp. (IBM - Analyst Report) and a tepid spending environment coupled with Accenture’s broad European exposure (roughly 40.0%) may temper its growth prospects to some extent.

Currently, Accenture has a Zacks #2 Rank (short-term Buy rating), which has been driven by upward revisions to analyst estimates.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%